MRKRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Marker Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.20+0.16 (+15.38%)
Close on Oct 19, 2026
- Market cap
- $23.18M
- P/E (TTM)
- –
- Dividend yield
- –
Marker Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBIR pancreatic cancer grant | $599.15K | $425.67K | – | – | – | – | – | – | – | – | – | – | 15.2% | – |
| SBIR AML | $500.71K | $472.21K | $590.91K | $690.91K | $878.91K | $982.18K | – | – | – | – | – | – | 12.7% | -43.0% |
| National Institutes of Health National - Cancer Institute Grant | $489.94K | $391.31K | – | – | – | – | – | – | – | – | – | – | 12.4% | – |
| FDA Grant | $131.38K | $118.48K | $129.75K | $139.75K | $239.75K | $519.75K | $720.00K | $700.00K | $600.00K | $400.00K | – | – | 3.3% | -45.2% |
| Grant income | – | $3.55M | $4.69M | $5.39M | $5.70M | $6.59M | $5.40M | $3.73M | $3.32M | $3.31M | $3.01M | $3.76M | – | – |
| CPRIT grant | – | – | $2.70M | $3.40M | $3.80M | $200.00K | $3.10M | $2.40M | $2.40M | $2.70M | – | – | – | – |
| SBIR lymphoma grant | – | $665.00K | $600.00K | $700.00K | – | $665.00K | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Marker Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.